Ozempic’s Hidden Workday Shocker

Doctor examining a digestive system model with a magnifying glass — WORKFORCE SHAKEUP

A new economic study says the same GLP-1 drugs now reshaping waistlines may also be quietly reshaping the workday by cutting long sick leaves by about one‑sixth.

Story Snapshot

Researchers found GLP-1 treatment is linked to a 17.3% drop in long-term sick leave among workers.
Long-term sick leave in the study means being out more than 30 days for health reasons.
The reduction in absence translates into fiscal gains equal to about 1.3% to 1.5% of yearly income per treated worker.
Employers now face a hard tradeoff: rich health and productivity benefits versus high drug costs and coverage questions.

Economic study finds fewer long sick leaves after GLP-1 treatment

Researchers from several universities dug into national health and labor records in Denmark to see what happens at work when people start GLP-1 medicine, such as drugs like Ozempic and Wegovy, that treat type 2 diabetes and obesity.

They focused on employed adults and tracked them for four years after they began treatment, then compared them to similar workers who did not start GLP-1 therapy until later.

GLP-1 drugs linked to 17% drop in worker sick leave, new economic study finds. https://t.co/h3Jjwf2KAI

— CBS News (@CBSNews) July 22, 2026

The working paper reports a clear number: GLP-1 treatment reduced long-term sickness leave by 17.3 percent over that four‑year window. Long-term sick leave here means medically certified absences lasting more than 30 days.

The researchers say that equals a drop of 0.95 percentage point, from a starting rate of 5.5 percent of workers taking such long leaves before treatment. That is not a small shift when scaled across a national workforce.

How big is the benefit in real money and real days?

The authors did not stop at percentages. They converted the change in sick leave into money, because employers and finance ministries care about budgets, not just bodies in chairs.

By their estimate, the cut in long-term sick leave alone is worth about 1.3 percent to 1.5 percent of annual labor income per treated employed person. In plain terms, that comes to roughly the value of several days of work each year for every worker on these medications.

They also looked beyond absence and found health use shifts in the right direction. Workers on GLP-1 drugs had fewer emergency department visits, used fewer heart medicines, and relied less on long-term sickness benefits.

When they assumed the same 17.3 percent improvement also applied to shorter sick spells, they calculated even more savings on top of the long-leave gains. The study frames these changes as “fiscal spillovers” that reach beyond the patient to employers and the government budget.

Why healthier workers matter more than the health plan bill

Health economists have warned for years that the highest cost of illness at work is not always the doctor bill. One multi‑employer analysis found that health‑related productivity costs, such as absence and working while sick, were on average more than double direct medical and pharmacy costs. That means keeping people on the job and functioning well can be worth two or three dollars for every dollar spent on care.

Other research shows how chronic conditions stack up. As workers move from two chronic conditions to three or more, their sick days jump sharply, from about 4.4 to 7.8 days per year in one report.

Conditions like depression, anxiety, obesity, back pain, and migraines all drive sizable productivity loss. From that lens, a class of drugs that improves weight, blood sugar, and heart risk at once looks less like a fad and more like a potential productivity tool, even if it was never sold that way.

What this means for employers wrestling with GLP-1 coverage

The study will land in the middle of a fierce debate in human resources offices. GLP-1 medications are expensive, and most employers are not legally required to cover them for weight loss.

A legal review notes that, while federal rules govern many health plans, none require coverage of GLP-1 drugs for obesity treatment. Employers generally choose whether to include these drugs, and many have been cautious.

GLP-1 drugs linked to 17% drop in worker sick leave, new economic study finds. https://t.co/h3Jjwf2KAI

— CBS News (@CBSNews) July 22, 2026

Cost-benefit analyses give a mixed picture. One review of health plan data found that GLP-1 users with diabetes saw medical costs fall by around 6 percent to 9 percent after about 30 months versus non-users, and weight-loss users saw 3 percent to 7 percent lower costs within 18 months.

But another case study reported drug costs near $6,540 per user per year, while medical savings were only about $560 annually, a short‑term loss for the employer’s balance sheet.

Productivity gains, worker morale, and conservative common sense

The Danish evidence suggests GLP-1s “work” in the sense that they help people stay on the job and out of long sick spells, with measurable fiscal gains.

At the same time, American employers are staring at steep pharmacy bills and no federal mandate that forces them to pick up the tab. That makes coverage a voluntary business choice, not a regulatory box to check.

There is also a cultural angle that many on the right care about: personal responsibility and trust at work. When one study tracked what happened after an employer stopped covering GLP-1 medicine for obesity, employees reported feeling devalued, burned out, and more likely to consider leaving their jobs.

If a medicine both improves health and signals that leadership cares, dropping coverage may save money on paper while raising the risk of turnover and resentment.